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Introduction
Chronic  persistent  cough  of  unknown  origin  is  a 
common  clinical  problem.  Therapies  have  been  de-
vised  for  chronic  cough  of  known  cause  such  as 
post-nasal  drip，  asthma  and  gastroesophageal  reﬂux1）. 
Yet，  the  pathophysiological  mechanisms  responsible 
for  chronic  cough  of  unknown  origin  are  not  clearly 
known，  although  this  condition  is  associated  with 
airway  inﬂammation  with  predominantly  mononucle-
ar-cell  inﬁltrates  and  epithelial  damage2）.  However， 
short-term  of  high  doses  of  inhaled  steroids  do  not 
always  effect  in  patients  with  chronic  cough2）.  Non-
sedating  selective  H1antihistamines3），4），5）  such  as  lo-
ratadine  and  terfenadine  may  be  of  clinical  use  for 
patients  with  chronic  cough.
Hypertonic  saline  inhalation，  which  induces  princi-
pally  the  release  of  histamine  from  airway  mast 
cells，  can  induce  bronchoconstriction  in  asthmatics， 
and  this  bronchoconstriction  can  be  inhibited  with 
H1antihistamines6），7）  or  nedocromil  sodium8），  and 
can  not  be  inhibited  with  NK1  receptor  antagonist9）. 
NK1  receptor  antagonist  do  not  also  inhibit  induced 
cough  in  asthmatics9）.  Hypertonic  saline  inhalation 
causes  cough  and  bronchoconstriction  in  asthmatics， 
and  these  responses  are  by  separate  neural  path-
ways10），11）.  On  the  other  hand，  it  is  reported  in  asth-
matics  that  responsiveness  to  4.5%  NaCl  inhalation 
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is  significantly  correlated  with  responsiveness  to 
methacholine，  but  is  not  signiﬁcantly  correlated  with 
responsiveness  to  water  inhalation12）.  We  previously 
experienced  that  loratadine  signiﬁcantly  reduced  the 
number  of  coughs  induced  by  ultrasonically  nebu-
lized  distilled  water  inhalation  in  patients  with 
chronic  cough13）.  However，  the  effect  of  H1antihista-
mine  on  ultrasonically  nebulized  hypertonic  saline-in-
duced  cough  has  not  been  yet  studied  in  non-asth-
matic  patients  with  chronic  cough  of  unknown  cause.
The  aim  of  this  study  was  to  determine  whether  a 
selective  H1antihistamine  can  reduce  the  number  of 
coughs  induced  by  ultrasonically  nebulized  hypertonic 
saline  inhalation  in  non-asthmatic  patients  with 
chronic  cough  and  normal  volunteers.  A  randomized， 
double-blind  cross-over  method  was  used.
METHODS
Subjects
Nine  non-asthmatic  patients  with  chronic  cough 
and  ten  normal  subjects  were  the  subjects  of  this 
study  （see  Table. 1）.  All  patients  and  subjects  were 
non-smokers.  The  duration  of  cough  was  from  two 
to  twelve  months.  Examination  of  all  patients  in-
cluded  a  respiratory  questionnaire，  physical  examina-
tion，  pulmonary  function  tests，  and  methacholine 
challenge  tests.  Methacholine  challenge  tests  were 
performed  three  or  ﬁve  days  before  hypertonic  saline 
inhalation  cough  challenge，  and  we  excluded  patients 
who  exhibited  hyperresposiveness  on  methacholine 
challenge  tests.  All  patients  had  normal  chest  and  si-
nus  radiographs.  None  had  any  history  of  esophageal 
reflux，  allergic  rhinitis，  or  post-nasal  drip.  None 
were  atopic，  as  determined  by  the  finding  of  at 
least  one  positive  reaction  to  skin  tests  in  a  battery 
of  twelve  common  airborne  antigens  or  speciﬁc  IgE 
antibodies  to  aeroallergens  or  both.  None  of  the  pa-
tients  had  a  history  of  post-viral  infection，  shortness 
of  breath，  wheezing  at  rest  or  use  of  ACE-inhibi-
tors.  None  had  a  history  of  airway  infection  during 
the  four-week  period  preceding  the  study.  None  took 
any  medication，  including  H1antihistamines，  preced-
ing  any  examination  in  the  study.  Informed  consent 
for  participation  in  the  study  was  obtained  from 
each  subject.  The  study  was  approved  by  the  Ethics 
Committee  of  Osaka  City  University  Hospital.
Hypertonic  Saline  Inhalation  Cough  Challenge
The  4.5%  NaCl  inhalation  tests  were  performed 
using  the  method  of  Anderson  et  al14）  with  some 
minor  modiﬁcations.  A  4.5%  NaCl  aerosol  was  in-
haled  from  an  ultrasonic  nebulizer  （Devilbiss  Ultra 
Neb  99，  The  Devilbiss  Co.，  Somerset，  PA，  USA） 
through  a  mouthpiece  connected  to  a  two-way  valve 
（Igarashi’s  non-rebreathing  valve，  Igarashi  Medical 
Co.，  Japan）  with  tubing  70  cm  in  length  and  22 
Table 1.  Characteristics  of  patients  and  normal  subjects
FVC （L） FEV1 （L） Cough  duration
Patients Age Sex （％ pred） （％ pred） FEV1/ FVC （months）
1 53 F 94 116 0.89 4
2 37 F 109 94 0.97 5
3 29 F 108 85 0.95 2
4 57 F 97 109 0.83 12
5 45 F 83 119 0.88 3
6 56 F 113 98 0.88 6
7 29 M 100 107 1.00 2
8 63 M 93 134 0.84 12
9 25 M 89 102 0.91 6
Mean 44 98 107 0.91 5.8
SD 14 10 15 0.06 3.8
Normal  subjects （n＝10.  aged  25-40  yrs，ﬁve  males  and  ﬁve  females）
Mean 30 98 98 0.91
SD 5.3 14 7 0.04
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mm  in  internal  diameter.  The  4.5%  NaCl  inhalation 
challenge  was  performed  during  tidal  breathing  over 
one  minute  with  the  subject  wearing  a  nose  clip. 
The  mean  output  of  the  nebulizer  without  a  two-way 
valve  was  15L/min，  and  particle  diameter  ranged 
from  0.5µm  to  5µm.  The  number  of  coughs  during 
the  one-minute  4.5%  NaCl  inhalation  and  the  30-sec-
ond  period  after  4.5%  NaCl  inhalation  were  counted 
by  an  observer  who  had  been  instructed  only  to 
count  and  record  in  a  tape  recorder.  No  coughs  after 
the  later，  30-second  period  were  counted.  Coughs 
were  deﬁned  as  plosive  events，  occurring  in  singles 
or  in  runs.  Each  plosive  event  was  counted  individu-
ally.  Episodes  of  throat  clearing  were  not  counted. 
Pulmonary  function  tests  （FVC:  forced  vital  capaci-
ty，  FEV1:  forced  expiratory  volume  in  one  second， 
V25:  maximum  expiratory  ﬂow  at  25%  vital  capaci-
ty;  Chestac-25  F  System，  Chest  Co.，  Ltd，  Tokyo） 
were  performed  every  two  minutes  before  and  after 
4.5%  NaCl  inhalation.  
Study  Design
Days  1  and  2
In  the  afternoon  of  the  visit  to  our  laboratory  on 
Day  1，  each  subject  inhaled  4.5%  NaCl  for  one 
minute，  and  the  number  of  coughs  during  the  one-
minute  4.5%  NaCl  inhalation  and  the  30-second  pe-
riod  after  4.5%  NaCl  inhalation  were  counted.  Then 
one  tablet  of  loratadine  （10mg，  Schering-Plough， 
Osaka，  Japan）  or  one  tablet  of  a  placebo  identical 
in  appearance  was  orally  administered  in  a  random-
ized，  double-blind  fashion.  Sixty  minutes  later，  one-
minute  4.5%  NaCl  inhalation  was  performed，  and 
the  number  of  coughs  was  counted  again.  Taking 
into  consideration  the  pharmacokinetics  of  loratadine， 
60-minute  intervals  were  included  between  4.5% 
NaCl  inhalations3），4）.  On  Day  2  of  the  study，  which 
was  two  days  after  Day  1，  each  subject  inhaled 
4.5%  NaCl  for  one  minute，  and  the  number  of 
coughs  was  counted.  On  Day  2，  either  placebo  or 
loratadine  was  administered，  whichever  was  not  ad-
ministered  on  Day  1.  Sixty  minutes  later，  one-min-
ute  4.5%  NaCl  inhalation  was  performed，  and  the 
numbers  of  coughs  were  counted  again.
Statistical  Analyses
Results  are  expressed  as  means  （SD），  but  num-
bers  of  coughs  （Fig. 2.3）  are  expressed  as  means 
（SE）.  Comparison  of  results  of  pretreatment  4.5% 
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Fig.  1.   Repeatability  of  pretreatment  number  of  coughs 
induced  by  4.5%  NaC1  inhalation  in  all  subjects.
Fig.  2.   Comparison  of  pretreatment  number  of  coughs 
induced  by  4.5%  NaC1  inhalation  between 
patients  and  normal  subjects.
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NaCl  challenges  between  Days  1  and  2  was  per-
formed  using  the  two-tailed  Student’s  t-test.  The  re-
peatability  of  results  of  the  pretreatment  4.5%  NaCl 
cough  challenges  was  assessed  using  the  Bland-Alt-
man  method15）.  The  mean  number  of  coughs  from 
the  Days  1  and  2  was  plotted  against  the  difference 
between  the  means.  Pre-treatment  differences  in  the 
number  of  coughs  between  groups  were  examined 
using  the  Mann-Whitney  U-test.  Differences  in  num-
bers  of  coughs  from  baseline  to  treatment  were  ana-
lyzed  using  Wilcoxon’s  rank-sum  test  when  compar-
ing  intragroup  differences.  Changes  in  recorded 
FEV1  were  studied  by  analysis  of  variance  （ANO-
VA）.  Findings  of  p＜0.05  were  taken  to  indicate 
statistical  signiﬁcance.
RESULTS
There  was  no  signiﬁcant  difference  between  pre-
treatment  numbers  of  coughs  on  Days  1  and  2  （p＝
0.8）.  The  calculated  coefﬁcient  of  repeatability  for 
4.5%  NaCl  challenge  was  3.4  （Fig. 1）.  Patients  with 
chronic  cough  had  a  signiﬁcantly  larger  response  to 
4.5%  NaCl  inhalation  testing  than  did  the  normal 
subjects  （Fig. 2）.  Neither  loratadine  nor  placebo  had 
any  effect  on  number  of  coughs  in  normal  subjects， 
Table 2.  Changes  in  FEV1  or  V25  from  control  to  each  period  of  1-minute  4.5％  NaCl
　       inhalation  in  placebo  day  and  loratadine  day （（P）＝placebo  day. （L）＝loratadine  day）
Patients 4.5% NaCl  inhalation 4.5% NaCl  inhalation
control → after →  drug → before → after p
FEV1 （L） 2.92 （0.8） 2.82 （0.8） Placebo 2.90 （0.7） 2.87 （0.8） n.s
FEV1 2.92 （0.8） 2.83 （0.8） Loratadine 2.87 （0.7） 2.83 （0.7） n.s
Normal  subjects
control → after →  drug → before → after p 
FEV1 3.42 （0.6） 3.39 （0.6） Placebo 3.35 （0.7） 3.34 （0.6） n.s
FEV1 3.44 （0.6） 3.44 （0.6） Loratadine 3.38 （0.6） 3.35 （0.6） n.s
mean （SD） 
Fig.  3.   The  effect  of  oral  administration  of  loratadine  on  the  number  of  coughs  induced  by  4.5% 
NaC1  inhalation.
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and  placebo  had  no  effect  on  this  parameter  in  any 
subject  group.  However，  compared  with  placebo， 
loratadine  signiﬁcantly  reduced  the  number  of  coughs 
in  patients  with  chronic  cough  （p＜0.02）  （Fig. 3）. 
There  was  no  signiﬁcant  difference  in  FEV1  or  V25 
before  to  after  4.5%  NaCl  inhalation  or  before  to 
after  oral  administration  of  placebo  or  loratadine  in 
either  patients  or  normal  subjects  （Table. 2）.
DISCUSSION
This  study  showed  that  for  non-asthmatic  patients 
with  chronic  cough，  oral  administration  of  lorata-
dine，  a  selective  H1antihistamine，  loratadine  signiﬁ-
cantly  reduced  cough  induced  by  4.5%  NaCl  inhala-
tion.  This  ﬁnding  suggests  that  it  provides  indirect 
evidence  that，  in  at  least  some  patients  with  chronic 
cough，  histamine  release  or  high  sensitivity  to  hista-
mine  response  to  change  in  airway  osmolarity  con-
tributes  to  the  cough.  This  ﬁnding  is  similar  to  our 
experience  that  loratadine  signiﬁcantly  reduced  the 
number  of  coughs  induced  by  ultrasonically  nebu-
lized  distilled  water  inhalation  in  patients  with 
chronic  cough13）.  In  asthmatics，  however，  respon-
siveness  to  4.5%  NaCl  inhalation  is  not  signiﬁcantly 
correlated  with  responsiveness  to  distilled  water  in-
halation12）.  These  suggest  that  4.5%  NaCl  inhalation 
and  distilled  water  inhalation  may  relate  to  differ-
ences  in  the  nature  mediators  released  or  synthesized 
in  response  to  each  challenge  for  asthmatics12），  but 
for  patients  with  chronic  cough，  both  may  be  simi-
lar  irritant  resulting  in  producing  cough.
A  previous  study  showed  that  in  non-asthmatics 
larger  amounts  of  hypertonic  saline  produce  small 
increases  in  non-specific  reactivity，  and  confirmed 
that  substantial  osmotic  challenge  does  not  change 
airway  calibre12），16）.  The  findings  of  no  significant 
difference  in  FEV1  or  V25  before  to  after  4.5% 
NaCl  inhalation  or  before  to  after  oral  administration 
of  placebo  or  loratadine  in  either  patients  or  normal 
subjects  indicate  that  loratadine  had  no  acute  effect 
on  bronchodilation  one  hour  after  its  oral  administra-
tion.  The  ﬁndings  of  the  present  study  suggest  that 
loratadine  reduces  the  number  of  coughs  induced  by 
4.5%  NaCl  inhalation  by  an  H1antihistamine  effect 
rather  than  an  anticholinergic  effect.
It  is  clear  that  cough  and  bronchoconstrictor  re-
ﬂexes  are  mediated  through  different  afferent  neural 
pathways10），11），17）.  Indeed，  bronchoconstriction  induced 
by  hypertonic  saline  inhalation  is  mediated  by  the 
release  of  histamine6），  but  analysis  of  induced  spu-
tum  has  revealed  no  difference  in  sputum  histamine 
level  between  asthmatics  and  normal  subjects18）. 
These  ﬁnding  suggest  that  asthmatics  may  have  a 
high  degree  of  sensitivity  to  the  bronchoconstrictor 
effects  of  hypertonic  saline  inhalation  without  change 
in  sputum  histamine  concentration.  On  the  other 
hand，  in  this  study  the  patient  group  had  a  signiﬁ-
cantly  larger  response  to  4.5%  NaCl  inhalation  than 
did  normal  subjects.  These  ﬁndings  suggest  that  pa-
tients  with  chronic  cough  exhibit  an  abnormally  ex-
cessive  reaction  to  stimulation  of  cough  receptors  by 
4.5%  NaCl  inhalation.  It  is  not  clear  why  hypertonic 
saline  induces  bronchoconstriction  in  asthmatics  and 
excessive  cough  in  non-asthmatic  patients  with 
chronic  cough.  Both  asthmatics  and  patients  with 
chronic  cough  have  a  bronchial  epithelial  damage 
with  inflammatory  cells2），18），19），20），  but  it  is  not 
clearly  known  that  following  stimulation  with  hista-
mine，  asthmatics  reﬂex  bronchoconstriction  and  pa-
tients  with  chronic  cough  reﬂex  cough  occur  and  are 
mediated  through  a  different  neural  pathways.    Fur-
ther  study  will  be  needed  to  clarify  these  mecha-
nisms，  and  it  will  be  necessary  to  follow  up  pa-
tients  with  chronic  cough  whether  they  have  asthma 
or  not.
H1antihistamines  inhibit  the  release  of  histamine 
and  leukotrienes  produced  by  eosinophils  and  mast 
cells21），22），23）.  H1antihistamines  are  known  to  be  ef-
fective  in  the  treatment  of  cough  in  patients  with 
nasal  disease1），24），  and  may  be  of  clinical  use  for 
patients  with  chronic  cough.
The  ﬁndings  of  the  present  study  show  that  in 
non-asthmatic  patients  with  chronic  cough，  H1anti-
histamine  signiﬁcantly  reduces  coughing  induced  by 
4.5%  NaCl  inhalation，  and  that  cough  receptors  in 
these  patients  have  a  high  degree  of  sensitivity  to 
irritation.  We  conclude  that  the  H1antihistamine  lo-
ratadine  reduces  cough  induced  by  hypertonic  saline 
inhalation，  and  that  in  patients  with  chronic  cough 
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the  release  of  histamine  or  the  high  sensitivity  of 
cough  receptors  to  histamine  may  contribute  to 
cough.  Hypertonic  saline  in  Ralation  is  mostly  wed 
for  sputum  induction  to  evaluate  airway  in  ﬂamma-
tion.25）
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